Abstract
Background: Globally, diabetic retinopathy (DR) has been identified as the cause of blindness among adults with both Type 1 diabetes (T1DM) and Type 2 diabetes (T2DM). Purpose: The study aimed to investigate the efficacy of Avastin in improving visual acuity (VA) and reducing central foveal (CFT) and parafoveal thicknesses (PFT) in participants with DR. Patients and Methods: A cross-sectional observational study was conducted at a tertiary hospital in the Gauteng Province (South Africa). A total of 55 participants were included in the study, with VA’s that were less than 0.5 LogMAR units and CFT’s greater than 300 microns (µm). Measurements of VA’s, CFT (µm), and PFT (µm) were conducted at baseline, after three and six months of receiving Avastin treatment. Numerical data were collected and analysed using IBM SPSS Version 28, and non-parametric tests were used to compare the means of the variables. Results: The mean VA improved from 1.00± 0.71 LogMAR at baseline to 0.66± 0.51 and 0.57± 0.48 LogMAR at 3 and 6 months, respectively (p < 0.001). The mean CFT improved from 441.22± 142.35 µm at baseline to 355.58± 129.38 µm and 308.40± 137.60 µm at 3 and 6 months, respectively (p < 0.001). The superior parafoveal thickness (SPFT) showed the highest decrease from a mean baseline of 379.04 µm to a mean baseline of 317.36 µm at 3 months. At 6 months, the decrease in the NPFT was statistically significant (p < 0.025) in improving VA. Conclusion: Early administration of Avastin treatment in diabetic patients is effective in reducing the mean CFT, NPFT, and improving the mean VA.

This publication has 13 references indexed in Scilit: